GRP-R agonistic 177-lutetium-labeled bombesin derivatives for diagnosis and treatment of prostate cancer

US9827338B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9827338-B2
Application numberUS-201514657802-A
CountryUS
Kind codeB2
Filing dateMar 13, 2015
Priority dateJun 16, 2014
Publication dateNov 28, 2017
Grant dateNov 28, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided is a novel compound capable of being usefully used to diagnose and treat prostate cancer by labeling a radioisotope on a bombesin derivatives capable of selectively targeting a target material over-expressed in tumor cells in order to develop an effective diagnose and treatment method of diseases associated with prostate cancer.

First claim

Opening claim text (preview).

What is claimed is: 1. A bombesin derivatives represented by the following Chemical Formula 2: [In Chemical Formula 2, n is an integer of 1 to 3, m is an integer of 1 to 5, R 1 and R 2 are each independently hydrogen or [c1-c5]alkyl, X is a metal chelator and G is a glucose group or derivatives thereof,] and A: *-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 . 2. The bombesin derivatives of claim 1 , wherein X includes one or more radioactive metal nuclides and is a metal chelator for a trivalent metal. 3. The bombesin derivatives of claim 2 , wherein the metal chelator for the trivalent metal is a DOTA-based chelator. 4. The bombesin derivatives of claim 2 , wherein the radioactive metal nuclide is for radiotherapy and is selected from the group consisting of 176 Yb, 111 In, 169 Gd, 177 Lu, 105 Rh, 111 Ag, 64 Cu, 67 Ga, 68 Ga, 125 I, 123 I, 129 I, and 166 Ho. 5. The bombesin derivatives of claim 1 , wherein in Chemical Formula 2, n is 3 and R 1 and R 2 are hydrogen. 6. The bombesin derivatives of claim 1 , wherein in G is R 3(s) are each independently hydrogen or a hydroxyl protecting group. 7. A preparation method of a bombesin derivatives comprising synthesizing a compound represented by the following Chemical Formula 2: [In Chemical Formula 2, n is an integer of 1 to 3, m is an integer of 1 to 5, X is a metal chelator, R 1 to R 2 are each independently hydrogen or (C1-C5)alkyl, A is *-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, and G is a glucose group or derivatives thereof[. 8. A composition for diagnosis and treatment of diseases associated with the prostate comprising the bombesin derivatives of claim 1 .

Assignees

Inventors

Classifications

  • the complex-forming compound being cyclic, e.g. DOTA · CPC title

  • A61K51/08Primary

    Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} · CPC title

  • Peptides; Proteins · CPC title

  • Gastrin releasing peptide (bombesin C07K7/086) · CPC title

  • C07K7/06Primary

    having 5 to 11 amino acids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9827338B2 cover?
Provided is a novel compound capable of being usefully used to diagnose and treat prostate cancer by labeling a radioisotope on a bombesin derivatives capable of selectively targeting a target material over-expressed in tumor cells in order to develop an effective diagnose and treatment method of diseases associated with prostate cancer.
Who is the assignee on this patent?
Korea Atomic Energy Res
What technology area does this patent fall under?
Primary CPC classification A61K51/08. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).